ArteraAI vs DoMore Diagnostics (2026)
Both extract a prediction about the future from tissue that has already been cut and stained, which is a harder claim than detecting what is present. ArteraAI builds multimodal cancer tests that combine image derived signal with clinical data, aimed at treatment decisions across more than one setting. DoMore is narrower and sharper, predicting outcome in stage two and three colorectal cancer, which is the specific decision where staging leaves oncologists genuinely unsure whether adjuvant chemotherapy is worth its harms. For a colorectal service that is the question worth answering and DoMore is built for it. Both are laboratory developed tests rather than cleared devices, so no regulator has reviewed either performance claim, and the validation cohort is what a buyer should interrogate rather than the headline hazard ratio.
- It builds multimodal cancer tests rather than a single slide model, which is a different evidentiary object and one that has been validated against treatment decisions.
- The prognostic question it addresses sits inside a treatment decision that is genuinely uncertain, which is where a test can change management rather than confirm it.
- Breadth beyond one tumour type gives an oncology service more than one place to use it.
- It predicts outcome in stage two and three colorectal cancer specifically, targeting the adjuvant chemotherapy decision where staging alone leaves clinicians guessing.
- Focus is the argument: one cancer, one decision, validated for that decision rather than a platform claim spanning tumour types.
- The signal comes from the standard stained slide the laboratory already produces, so no additional tissue or assay is required.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. ArteraAI and DoMore Diagnostics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | ArteraAI | DoMore Diagnostics |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | Not recorded | 2020 |
| Headquarters | Los Altos, California | Oslo, Norway |
| Website | artera.ai | domorediagnostics.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards ArteraAI its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against DoMore Diagnostics, ArteraAI grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards DoMore Diagnostics its top capability grade on AI Centrality and Clinical and Operational Evidence. Set against ArteraAI, DoMore Diagnostics grades higher on EHR and Interoperability Depth. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose ArteraAI or DoMore Diagnostics?
On the axes where the AI Health Index separates them, ArteraAI grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure, and DoMore Diagnostics grades higher on EHR and Interoperability Depth. ArteraAI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do ArteraAI and DoMore Diagnostics differ most?
The widest separation the AI Health Index records between ArteraAI and DoMore Diagnostics is on Model Supply Chain Disclosure, where ArteraAI grades B and DoMore Diagnostics grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do ArteraAI and DoMore Diagnostics grade the same?
The AI Health Index grades ArteraAI and DoMore Diagnostics the same on several axes, including AI Centrality, Clinical and Operational Evidence and AI Liability and Recourse. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have ArteraAI and DoMore Diagnostics not disclosed?
At the last review, at least one of ArteraAI and DoMore Diagnostics published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both are laboratory developed tests rather than cleared devices, so no regulator has reviewed the performance claims and the validation cohorts are the thing to interrogate: ask how closely they match your own population by stage, ancestry and treatment era, since practice changes make older cohorts less informative. Neither publishes a security attestation.
The shared technical exposure is that models trained on slides from particular laboratories inherit those laboratories' staining and scanning characteristics, so performance can degrade on tissue prepared elsewhere with no visible signal.